last updated: 10 September 2020Follow us on Twitter @CCP2020HD
17 September, 4-9 pm (CEST)
Michael Baumann, German Cancer Research Center
Franz Kohlhuber, German Cancer Aid
Greetings of the German Ministries
Thomas Rachel, Federal Ministry of Research and Education
Sabine Weiss, Federal Ministry of Health
Chair: Michael Baumann
Introductory Lecture: Elisabete Weiderpass, International Agency for Research on Cancer
Global cancer burden and research priorities for cancer prevention
Primary Cancer Prevention
Research in risk factors aiming for practical interventions
Chairs: Rudolf Kaaks & Thomas Seufferlein
Keynote: C. Richard Boland, University of California San Diego
Genetic mechanisms involved in colorectal tumor formation and the implications for prevention
Tilman Kühn, Queen's University Belfast
Obesity and cancer: From mechanisms and associations to prevention
Silvia de Sanjose, National Cancer Institute (consultant), PATH
Steps towards the control of cervical cancer in low resource settings
Rebecca Fitzgerald, University of Cambridge
Primary prevention of upper GI cancer
Olivera J. Finn, University of Pittsburgh
Vaccines for the prevention of colon and other non-viral cancers
Secondary Cancer Prevention
Prostate and Breast Cancer Screening
Chairs: Sebastian Bickelhaupt & Peter Albers
Keynote: Monique J. Roobol, Erasmus University Medical Center
Prostate Cancer Screening – present and future perspectives
Heinz-Peter Schlemmer, German Cancer Research Center
Emerging imaging methods for early detection of breast and prostate cancer
Minetta Liu, Mayo Clinic Rochester
Novel molecular markers for early cancer detection
Rita Schmutzler, University Hospital Cologne
Challenges for increasingly personalized breast cancer screening and risk assessment
18 September, 4-9 pm (CEST)
Primary Cancer Prevention
Cancer Prevention in Europe
Chairs: Ute Mons & Jérôme Foucaud
Keynote: Joachim Schüz, International Agency for Research in Cancer
The European Code against cancer
Isabelle Soerjomataram, International Agency for Research on Cancer
Large burden of cancer in Europe can be averted through primary prevention
Alison Cox, Cancer Research UK
Role of health policy in cancer prevention
Secondary Cancer Prevention
Chairs: Ulrike Haug & Ulrike Peters
Keynote: Hormuzd Katki, National Cancer Institute
Risk Stratification in Lung Cancer Screening
Beatriz Carvalho, Netherlands Cancer Institute
Molecular risk classification of adenomas: Current knowledge and future potential in colorectal cancer early detection
Suzette Delaloge, Gustave Roussy, MyPeBs
Risk-stratified screening approaches for breast cancer – update from the personalized breast screening MyPeBs
Peter Albers, University Hospital Düsseldorf
Update and future perspectives on PROBAse and PRiMA, prostate cancer screening and early detection in prostate cancer
Tertiary Cancer Prevention
Improving life with and after cancer
Chairs: Karen Steindorf & Hermann Brenner
Keynote: Jeffrey Meyerhardt, Dana-Farber Cancer Institute
The potential of tertiary prevention: the example of colorectal cancer
Lonneke van de Poll, Netherlands Cancer Institute
How to improve patient-centeredness of cancer care?
Julienne Bower, University of California Los Angeles
Biological mechanisms of cancer-related fatigue
Ben Schöttker, German Cancer Research Center
Role of co-medication in tertiary cancer prevention
Chair: Ernest Hawk
Perspectives Lecture: Timothy Rebbeck, Dana-Farber Cancer Institute
Cancer prevention and early detection in the precision medicine era
Michael Baumann, German Cancer Research Center
17 September, 5-7 pm (CEST)
Workshop: Secondary prevention of Prostate Cancer
Chairs: Peter Albers
Christian Arsov, University Hospital Düsseldorf
Lars Schimmöller, University Hospital Düsseldorf
Short biographies (A-Z)
- gradually being revealed
Follow us on Twitter @CCP2020HD
Peter Albers, MD, is Professor and Chairman of the Department of Urology, Heinrich-Heine-University Düsseldorf since 2008. In January 2018 he was elected Medical Director of the CIO Düsseldorf, Comprehensive Cancer Center at the University Hospital Düsseldorf. In January 2020 he was double appointed Division Head of the newly established Division “Personalized Early Detection” in the National Cancer Prevention Center of the German Cancer Research Center (DKFZ) in Heidelberg. Prof. Albers received his MD degree from the University Mainz and started his surgical training and urological residency at the Universities of Mainz and Bonn. He obtained a German Research Foundation (DFG) Research Fellowship at the Department of Urology, Indiana University (Indianapolis) and at the Department of "Cancer Research" Eli Lilly, Inc. (Indianapolis, USA) in 1993-1994. From 1998-2003 Prof. Albers was Vice Chairman of the Department of Urology at the University of Bonn and from 2003-2008 Chairman of the Department of Urology at the Klinikum Kassel GmbH, Marburg University. Since 2008 he is Professor and Chairman of the Department of Urology at the Heinrich-Heine-University Düsseldorf. Peter Albers received numerous awards, such as the Maximilian-Nitze-Award of the German Society of Urology in 1999 and 2002, the Alken Prize and the John-Mendelsohn Study-Award of the German Cancer Society in 2010. Prof. Albers led the EAU Testis Cancer Guidelines Group from 2006 to 2018 and chaired as Congress President the German Cancer Congress in 2012. From 2016 to 2018 Peter Albers was President of the German Cancer Society. 2019 he was appointed Chair of the Scientific Congress Office and Board Member of the European Association of Urology (EAU). His major scientific interests are prostate cancer screening (www.probase.de), mpMRI imaging in prostate cancer, testis cancer pathogenesis and prognosis and bladder cancer clonal evolution.
C. Richard (Rick) Boland
C. Richard (Rick) Boland, MD, AGAF, is a gastroenterologist and Professor of Medicine at the University of California San Diego School of Medicine. He is from upstate New York, USA, received a BA from The University of Notre Dame and an MD from Yale Medical School. He has a career-long research interest in colon cancer, specifically focusing on the genetic causes of colon cancer and familial cancer syndromes. Dr. Boland started studying familial colorectal cancer as a medical student, where he proposed a novel familial aspect of the disease. His initial research was with Young S. Kim, MD, at UCSF, studying glycoprotein biochemistry in colorectal cancer. In 1990, at the U of Michigan, he turned his focus to the molecular genetics of colorectal cancer in a sabbatical in the HHMI, and resumed work on the hereditary colorectal cancer disease, which he named “Lynch Syndrome.” He was among the first gastroenterologists to explore “microsatellite instability” in cancer, and his laboratory developed the first in vitro models to study the basic biology of Lynch Syndrome. In recent years, he has contributed to our understanding of the genetic and epigenetic basis of colorectal cancer. Dr. Boland has been funded continuously by NIH since 1979, has served on multiple NIH (and other) Study Sections and was the chair of the Clinical Integrative Molecular Gastroenterology Study Section from 2014 to 2016, and was on the Multisociety Task Force on Colorectal Cancer from 2012-18. He has published over 400 papers, has an H-Index of 92, and has written authoritative chapters for several textbooks of Internal Medicine, Gastroenterology and Genetics. He was elected into the Association of American Physicians in 2001. Dr. Boland was president of the American Gastroenterological Association (AGA) from 2011-2012, was given the AGA Oncology Section Distinguished Mentor Award, the AGA Beaumont Prize for his research in 2015, and the AGA Friedenwald Medal in 2016.
Dr. Julienne Bower is a Professor of Psychology and Psychiatry/Biobehav-ioral Sciences at the University of California Los Angeles (UCLA) and Research Scientist in the Cousins Center for Psychoneuroimmunology in the Semel Institute for Neuroscience and Human Behavior. Her research focuses broadly on bidirectional interactions between inflammation and psychologi-cal/behavioral states among individuals facing stressful life events. A central focus of her research has been understanding the biological mechanisms underlying fatigue and other behavioral disturbances in cancer patients and survivors. She has identified an inflammatory basis for cancer-related fatigue as well as biobehavioral risk factors for this symptom, including alterations in immune regulatory systems, cytokine gene polymorphisms, and early life stress. Another line of her research examines how stress influences physical health, with a focus on tumor biology, and resilience factors that may buffer the negative effects of stress exposure. Dr. Bower has also been actively involved in developing mind-body interventions for cancer populations and testing effects on psychological and immune outcomes.
Beatriz Carvalho is a molecular biologist with a specific interest in colorectal adenoma to carcinoma progression and in the use of this knowledge for identification of better markers for early detection of colorectal cancer. After completing her PhD in 2001 in the area of gastric cancer she started a postdoctoral position in colorectal cancer, focusing on the biology of progression from adenoma to carcinoma, at the department of Pathology of the VU University Medical Center in Amsterdam. Since 2015, Dr. Carvalho has a senior scientist position at the Netherlands Cancer Institute (Amsterdam). The use of omics technology (DNA, RNA and protein level) facilitated the finding of several candidate genes putatively involved in colorectal progression, which are being followed up by in vitro functional studies using organoid culture systems. During the past years Dr. Carvalho has, next to understanding the biology of progression, worked also on the identification of biomarkers for early detection of colorectal cancer. One of the molecular drivers of adenoma-to-carcinoma progression is the occurrence of driver DNA copy number alterations, which can aid in the estimation of risk of progression and therefore be good intermediate endpoints in screening and/or surveillance of CRC. Dr. Carvalho is actively involved not only in the discovery but also in the validation of the research findings in order to translate these in the clinical setting.
Alison Cox is Director for Cancer Prevention at Cancer Research UK, responsible for the charity's policy and strategic direction in the area of cancer prevention. At CRUK Alison led the campaign that has put tobacco in plain, standardized packaging, and the development of an e-cigarette research and engagement strategy that has established the charity as the leading research funder in this field. She has built on CRUK’s tobacco control success by developing an obesity strategy and a campaign on restrictions on junk food marketing to children. Alison has also developed and delivered CRUK’s return to investment in international tobacco control, leading a £5million initiative to deliver policy research and advocacy to support the implementation of the WHO Framework Convention on Tobacco Control in low- and middle-income countries.
Suzette Delaloge, MD, MSc, is an Associate Professor of Medical Oncology. She trained in France and Canada. She has been Head of the Breast Cancer Department at Gustave Roussy, Paris, France since 2004 and currently leads a multidisciplinary team of 70. Dr. Delaloge’s major areas of expertise are breast cancer oncology, precision oncology, precision risk-based cancer prevention, and the organization of care in oncology. She is past president of the French National Breast Cancer Research Intergroup UCBG. She chairs the large European H2020 EU-funded MyPeBS consortium, which aims at demonstrating the value of risk-based breast cancer screening among 85000 randomized women. Dr. Delaloge is the author of more than 240 international peer-reviewed publications and more than 500 presentations at international conferences (Scopus H-index: 50). She is a board member of the European Society of Medical Oncology (ESMO) and of the French Society of Breast Care and Breast Pathology, and participates to the elaboration of numerous national and international guidelines. Dr. Delaloge is breast specialty editor for European Journal of Cancer, genetics editor for The Breast, and a member of the international advisory board of The Lancet Oncology.
Olivera J. Finn
Dr. Finn is University of Pittsburgh Distinguished Professor of Immunology and Surgery and Founding Chair of the Department of Immunology. After receiving her PhD in Medical Microbiology at Stanford University in 1980 and completing her postdoctoral training in Immuno-oncology there in 1982, Dr. Finn started her research at Duke University and in 1991 moved to the University of Pittsburgh. She gained prominence through her basic and applied research on tumor antigens and cancer vaccines, in particular vaccines for the prevention of non-viral cancers, published in over 200 articles and over 70 reviews and book chapters. She serves on advisory boards of several cancer centers, including DKFZ, and on editorial boards of many cancer journals. Dr. Finn is member of the American Association of Immunologists (AAI) where she served as President in 2007/2008. She is a recipient of many awards and honors including the AAI Life Time Achievement Award, the NCI Outstanding Investigator Award, the AACR CIR Lloyd Old Cancer Immunology Prize and the SITC Smalley Award. She is AAI Distinguished Fellow.
Rebecca Fitzgerald is Professor of Cancer Prevention and Interim Director at the MRC Cancer Unit, University of Cambridge. She co-leads the Early Detection Programme of the CRUK Cambridge Centre which is part of the International Alliance in Early Detection (ACED) and still practices medicine as Hon Consultant in Gastroenterology at Addenbrooke's Hospital. The focus of her research group is to investigate the steps in malignant transformation in the oesophagus and stomach and to use this information to improve clinical early detection strategies. Her work to develop the Cytosponge and related biomarker assays for detection of Barrett's oesophagus and associated dysplasia has been awarded a number of prizes including the Westminster Medal, the BMJ Gastro team of the year, an NHS Innovation prize and the CRUK Jane Wardle Early Detection Prize. In 2013, she was elected as a Fellow of the Academy of Medical Sciences. Rebecca is committed to teaching and is a Fellow of Medical Sciences at Trinity College Cambridge.
Tilman Kühn is a Lecturer in Nutritional Epidemiology at Queen’s University Belfast, with an adjunct position at the Heidelberg Institute of Global Health (HIGH). His research focus is on the effects of diet, body composition and metabolism in the development of cancer and chronic diseases. Many of his publications in this area are based on data from the EPIC-Heidelberg cohort that he worked on as a research assistant, post doc, and group head since 2010 in the Division of Cancer Epidemiology at DKFZ Heidelberg. Tilman is strongly interested in obesity prevention, and was the PI of the HELENA-Trial, a 2-year RCT to evaluate the metabolic effects and practicability of intermittent fasting among overweight persons. He is active in the German Society for Epidemiology (speaker, nutrition group) and the German Nutrition Society (guideline author, board member).
Minetta C. Liu, MD, is a breast medical oncologist and translational researcher at the Mayo Clinic in Rochester, MN, where she holds dual appointments in the Department of Oncology and the Department of Laboratory Medicine and Pathology. Her primary research focus is on the efficient advancement of novel therapeutics and the development of reliable predictors of systemic treatment response. As such, she leads several research trials with both clinical and correlative laboratory endpoints. She holds the academic rank of Professor of Oncology from the Mayo Clinic College of Medicine. Dr. Liu is Chair of Research for the Department of Oncology, Co-director of Genomics in Action for the Center for Individualized Medicine, a member of the Mayo Clinic Research Committee, Institutional Principal Investigator for the Translational Breast Cancer Research Consortium, Associate Medical Director for the Department of Development, and Medical Director for the Office of Specialty Contracts and Collaborations. She serves on the Breast Committee for the Alliance for Clinical Trials in Oncology, leads the Circulating Biomarker Working Group for the NIH Translational Research Program, and directs a laboratory focused on expanding the clinical applications and advancing the technologies related to liquid biopsies for solid tumors. She is dedicated to improving patient outcomes through access to novel therapeutic agents and molecular diagnostic tools.
Jeffrey Meyerhardt earned his medical degree from Yale University School of Medicine, completed residency in medicine at Beth Israel Deaconess Medical Center in Boston, MA and fellowship at the joint Dana-Farber Cancer Institute, Massachusetts General Hospital, and Brigham and Women’s Hospital hematology/oncology program. Dr. Meyerhardt also holds a Masters of Public Health from Harvard School of Public Health in Boston. Dr. Meyerhardt is a Douglas Gray Woodruff Chair in Colorectal Cancer Research, serves as the Clinical Director for the Gastrointestinal Cancer Center, and Deputy Clinical Research Officer at Dana-Farber. He is a Professor of Medicine at Harvard Medical School. Dr. Meyerhardt’s research interests are focused on the influence of diet and lifestyle on outcomes among patients with cancer, particularly colorectal cancer. He served as a project leader on Dana-Farber/Harvard Cancer Center’s TREC and GI SPORE grants. He has led multiple phase II trials for gastrointestinal cancers and is the principal investigator for an ongoing NCI-sponsored phase III adjuvant therapy for stage III colon cancer. He has presented nationally and internationally and published extensively on related topics in peer-reviewed journals and book chapters. Dr. Meyerhardt is a member of the American Society of Clinical Oncology, serving on multiple committees including the Clinical Practice Guidelines Committee, Conquer Cancer Foundation Grants Selection Committee, Annual Meeting Scientific Program Committee, and Cancer Education Committee, and is an associate editor for Cancer.net. He co-chairs the Gastrointestinal Cancer committee for the Alliance NCI cooperative group.
Dr. Katki’s research focuses on understanding how epidemiologic findings could be used for cancer screening and prevention. He is particularly interested in developing individualized risk-based approaches to cancer screening. His methodologic research focuses on estimating individual absolute risk, strategies for risk-based screening and management, and metrics for evaluating risk models and biomarkers.
Lonneke van de Poll
Lonneke van de Poll-Franse is Professor of Cancer Epidemiology and Survivorship at Tilburg University and group leader at the department of Psychosocial research and Epidemiology at the Netherlands Cancer Institute in Amsterdam, The Netherlands. Her research focuses on quality of life and quality of care in the field of cancer survivorship. Lonneke has a special research interest in the impact of cancer and its treatment on patient reported outcomes (symptoms, health related quality of life) during cancer survivorship. In 2009, she started the PROFILES (Patient Reported Outcomes Following Initial treatment and Long-term Evaluation of Survivorship) registry that combines population-based cancer registry data with patient reported outcomes (www.profilesregistry.nl). She is an active member of the EORTC-QoL group and PI for the development of a lymphoma module and EORTC Cancer Survivorship questionnaire.
Dr. Timothy Rebbeck is the Vincent L. Gregory, Jr. Professor of Cancer Prevention at the Harvard T.H. Chan School of Public Health and the Dana-Farber Cancer Institute. He is founding director of the Zhu Family Center for Global Cancer Prevention at the Harvard T.H. Chan School of Public Health and leads the Cancer Outreach and Engagement activities for the Dana-Farber Harvard Cancer Center. He leads molecular epidemiology studies to address problems of cancer etiology, prevention, outcomes, health disparities, and global health. His work has led to an understanding of the genetic and environmental causes of breast, prostate, skin, endometrial and ovarian cancers as well as interventions intended to reduce the burden of these cancers in individuals and populations. He founded and leads international cancer consortia that study risk and outcomes of 1) cancer in BRCA1/BRCA2 mutation carriers, and 2) prostate cancer in men of African descent in North America and Africa.
Monique Roobol is Professor Decision Making in Urology and the Head of the scientific research office within the Department of Urology at Erasmus Medical Centre Rotterdam, The Netherlands. She has a masters and a PhD degree in epidemiology. The last twenty years have been completely dedicated to research on the early detection of prostate cancer. Next to her significant contribution to the European Randomized study of Screening for Prostate Cancer (ERSPC: www.erspc.org ), she co-developed the “Rotterdam Prostate Cancer Risk calculator: www.prostatecancer-riskcalculator.com,” a multi-step risk analysis tool to guide laymen and physicians in decision making at diagnosis and the study on active surveillance (PRIAS: Prostate Cancer Research International Active Surveillance (www.prias-project.org)). The scientific research office performs and supports several clinical and population-based screening studies. On average five PhD students are working under Prof. Roobol’s guidance. She is now the PI of ERSPC and co-PI of PRIAS and the Movember Global Action Plan-3 (active surveillance). Since 2018, she is part of the PIONEER European network for big data in prostate cancer (https://prostate-pioneer.eu/). She is the chairwoman of the Dutch Prostate Cancer Research Foundation (SWOP). Prof. Roobol has (co)-authored over 350 scientific publications, book chapters and reviews, is an advisory board member of several major trials related to prostate cancer. Her research has been awarded with several prices, such as the European Urology Platinum Award 2011 and 2018 and the BJUI best urological mobile application award 2015. Her motto is: translate research into useful tools for use within clinical practice: “Bridging the gap between epidemiology and urology”
Silvia de Sanjosé
Dr. Silvia de Sanjosé is a health professional with over 30 years of expertise in epidemiology of HPV and related cancers. She has led in large international studies involving HPV technology on genotyping and on screening implementation activities. Through her work at the Catalan Institute of Oncology, Dr. de Sanjosé worked on several projects and studies regarding HPV and cervical cancer prevalence, HPV technology and protocols, and HPV genotyping. She is involved in several projects on the relationship between HPV and HIV. She served as the President of the International Papillomavirus Society. Dr. de Sanjosé holds both a Master of Science and PhD in Epidemiology from the London School of Hygiene and Tropical Medicine. Currently she is serving as Senior adviser to NCI and PATH. Dr. de Sanjosé has led the Scale-Up project on HPV molecular tests in Nicaragua, Guatemala, Honduras and El Salvador and is the PI of the NCI The Automated Visual Evaluation Network project. She is Associate professor at the University of Washington.
Heinz-Peter Schlemmer is head of the Division of Radiology at the German Cancer Research Center and professor for Oncologic Radiology at the Medical Faculty of Heidelberg University, Germany. Following his academic studies in physics and medicine, he worked at several national and international University hospitals and research institutions. His scientific interest is devoted to the development and clinical application of oncologic imaging technologies for improving cancer detection and characterization by using morphological and functional MRI at 1.5 T up to ultra-high 7.0 T, dual-energy and photon-counting CT and PET/MRI. His particular research focus is on imaging prostate cancer. The research work comprises multiparametric and multimodal imaging including most recent research advantages in bioinformatics for image analyses. The technologies are applied for early detection and staging as well as treatment planning, guidance, and monitoring. Focusing on oncologic imaging, he is actively engaged in national and international societies. He was president of the International Cancer Imaging Society, and from 2021 onwards, he will be president of the European Society of Oncologic Imaging.
Rita Schmutzler is a specialist in Obstetrics and Gynecology, director of the Center for Familial Breast and Ovarian Cancer, University Hospital Cologne and co-ordinator of the German Consortium for Hereditary Breast and Ovarian Cancer. She is member of numerous committees such as the expert panel of the National Cancer Plan at the Federal Ministry of Health, the S3 guideline committee on breast cancer, the committee of the gene diagnostic act, the scientific advisory boards at the Federal Institute for Drugs and Medical Devices (BfArM) and the Institute for Quality and Efficiency in Health Care (IQWIG). Her main focus is to understand the hereditary basis of breast and ovarian cancer, identify genotype-/phenotype correlations and translate these findings into risk-adjusted clinical prevention programs.
After his studies of pharmacy and the practical year he received the license as a pharmacist. In addition, he completed postgraduate Masters in "Public Health" and "Pharmacovigilance and Pharmacoepidemiology". After completing his doctorate at the Institute of Social Medicine at the University of Lübeck, he joined the Department of Clinical Epidemiology and Aging Research at the DKFZ in October 2009 for the postdoctoral phase and has been working in this position without interruption for 11 years now. Ben Schöttker is currently working in the area of pharmaco-epidemiology with a focus on the drug safety for elderly cancer patients.
Dr. Joachim Schüz
Dr. Joachim Schüz is a senior cancer epidemiologist. Since 2010, he is Head of the Section of Environment and Radiation at the International Agency for Research on Cancer (IARC), the cancer research agency of the World Health Organisation (WHO), in Lyon, France. Objectives of research in the Section are the identification of causes of cancer related to environmental pollutants, occupational exposures, some lifestyle factors, and radiations (ionizing and non-ionizing). In 2020, he additionally became Acting Head of the Section of Early Detection and Prevention at the IARC. Related to cancer prevention, Dr. Schüz is Chair of the newly established network “Cancer Prevention Europe”, a consortium of key cancer prevention institutions in Europe, and is leading the 4th edition of the European Code against Cancer. Before moving to the IARC, Dr. Schüz was working at the Danish Cancer Society Research Center in Copenhagen and at the University of Mainz, Germany, where he received his PhD in 1997 and his professorial qualifications (Habilitation) in 2002. Dr. Schüz worked in the field of cancer epidemiology throughout his career.
Isabelle Soerjomataram is a medical epidemiologist with a special interest in cancer prevention. She received her medical degree from the University of Indonesia in 2001. Following a PhD in cancer epidemiology (2007) at the Public Health department at Erasmus MC in Rotterdam, she went to the Harvard School of Public Health to work on global indicators of cancer burden. She took a position at IARC in 2011 where she is currently assessing international variation of the cancer burden using mainly population-based datasets. In addition to her research activities, she is (co)coordinating several large projects funded by various institutions including the Cancer Research UK, WCRF, the National Cancer Institute in France or WHO regional offices. For example in France, she coordinated the estimation of the proportion of cancer attributable to all known lifestyle and environmental risk factors to support national cancer plans and communication. More internationally she is leading the global estimation on burden cancers related various risk factors. Other projects that she leads are cancer survival projects, in high-income and also low-and middle income settings assessing the effectiveness of the local health system as well as influence of major risk factors such as obesity.
Elisabete Weiderpass, MD, MSc, PhD, is a Brazilian cancer researcher who is a naturalized Swedish and Finnish citizen. She is an expert in cancer epidemiology and cancer prevention. In January 2019, Dr. Weiderpass took office as elected Director of the International Agency for Research on Cancer (IARC, www.iarc.fr), the specialized cancer agency of the World Health Organization (WHO), based in Lyon, France. The Agency welcomes about 350 staff dedicated to cancer research. Its membership and governance is made up of 27 countries (or ‘participating States’), including Germany. Dr. Weiderpass previously served as Head of the Department of Research at the Cancer Registry of Norway, and of the Genetic Epidemiology Group at the Folkhälsan Research Center in Finland. She was a Professor of Medical Epidemiology at the Karolinska Institutet in Stockholm, Sweden, and a Professor of Cancer Epidemiology at the Arctic University of Norway. She held Adjunct Professorship positions in Cancer Epidemiology in Brazil, China, and the Islamic Republic of Iran, and is a Visiting Professor in Kuwait. Dr. Weiderpass has authored over 800 scientific publications in peer-reviewed international journals.